Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial

The authors of a commentary suggest that the immunogenicity equivalence of the dose-sparing, and thus cost-sparing, intradermal vaccine could have a major effect on zoster vaccine cost effectiveness analyses, though clinical efficacy still needs to be addressed for this intradermal formulation. However, they consider the current immunogenicity data to be promising.